Feature | December 26, 2013

IMV Market Report Shows Nuclear Medicine Providers are Consolidating as Procedure Volume Slows

nuclear imaging spect spect/ct IMV
December 26, 2013 — A report released by IMV Medical Information Division found that providers of nuclear medicine (NM) services are consolidating as procedure volume dropped in the subspecialty from 2008 to 2012. 
 
An estimated 14.5 million nuclear medicine patient studies were performed on 14,825 single-photon emission computed tomography (SPECT) or SPECT/CT in the United States in 2012. Compared with the 16 million patient studies performed in 2008, total nuclear medicine patient studies have decreased about 9 percent, for an average annual decline of 2.5 percent per year from 2008 to 2012. 
 
“We attribute this decline in NM patient studies to several factors, including the impact of precertification requirements from health insurance companies, reduced reimbursement and studies shifting to competing technologies, such as bone studies shifting to PET,” said Lorna Young, senior director of market research, IMV. 
 
IMV’s study also shows that physician practice locations (primarily cardiology practices) are feeling financial pressure due to reduced reimbursement from Medicare and third-party payors. When asked about the issues affecting their future outlook, both hospitals and non-hospitals responded that “reductions in Medicare and third-party reimbursements are causing NM revenue to decline” is their top-rated issue, but managers of physician practices are more likely to rate this as a top issue than are administrators of hospital nuclear medicine departments. 
 
Due to these pressures, the number of physician practices performing nuclear medicine studies has declined 6 percent over the past two years, and this decline is likely to continue. 
 
Respondents from physician office locations were asked if they were planning to pursue certain strategic actions over the next few years, including changing their practice ownership structure to include a joint venture with hospitals. Almost one-third of the respondents are either considering or planning such a change in their practice model. 
 
This in turn is impacting their purchase plans for nuclear medicine cameras. While 29 percent of the nuclear imaging sites in the survey are independent physician office locations, less than 10 percent of the sites planning camera purchases through 2015 will be physician offices. 
 
According to the report, while the nuclear medicine market is currently slowing down with the decline in patient studies and a reduction in the number of sites performing NM studies, there is a relatively large installed base of aging equipment. Of the sites that are planning to purchase NM cameras, almost 90 percent of the planned purchases will be for replacement units.
 
Based on market scenarios for unit sales from 2013 to 2017 provided in the report, IMV anticipates that the years 2015-2017 will be relatively active years for system replacements. One driver for replacement activity is the SPECT/CT camera, which will comprise at least 40 percent of the planned purchases for nuclear medicine cameras.
 
IMV’s 2013 Nuclear Medicine Market Outlook Report describes trends in nuclear medicine patient volume by study type, radiopharmaceutical and pharmacological stress agent utilization, SPECT versus SPECT/CT camera installed base and purchase plans, site operations characteristics and department managers' opinions about the factors affecting the future outlook for nuclear medicine.
 
In the report, IMV also provided market scenarios for nuclear medicine camera purchases from 2013 through 2017. Vendors covered in this report include Cardinal Health, Digirad, GE, Philips, Siemens, Spectrum Dynamics and Triad. 
 
Additional highlights include:
  • A larger 80 percent proportion of the NM studies conducted in nonhospital locations are cardiovascular studies, compared with 46 percent of those conducted in hospitals. Hospitals are more likely to be conducting other procedure types, including bone scans, liver/hepatobiliary, renal, respiratory, infection/abscess and tumor localization studies. 
  • An estimated 8 million myocardial ischemia perfusion studies were performed in 2012, of which 58 percent used pharmacological stress agents, either alone or with exercise. 
  • Just over 25 percent of sites indicated providing neurology applications, and this may grow to more than one-third by 2016.
 
IMV's 2013 Nuclear Medicine Market Outlook Report is based on the responses to an IMV-hosted online survey from 410 nuclear medicine department/facility managers nationwide. Responses were projected to the universe of 6,985 short-term general hospitals, imaging centers and physician practices in the United States that have fixed nuclear medicine cameras as identified by IMV. 
 
For more information: www.imvinfo.com

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init